Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NS-050 (NeuShen Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Nippon Shinyaku
- Administration
- Intravenous
01
Overview
NS-050 is an investigational drug candidate currently in the discovery stage, developed by NeuShen Therapeutics. It is being developed for the treatment of treatment-resistant depression (TRD), Alzheimer's disease, and Parkinson's disease. NeuShen Therapeutics is a biotechnology company with operations in Shanghai and Boston that specializes in central nervous system (CNS) disorders, utilizing both small molecule discovery and AAV-based gene therapy platforms. As of early 2024, specific details regarding the biological target, mechanism of action, and modality of NS-050 have not been publicly disclosed by the developer.
02
Targets
DMD (Dystrophin)
Beyond the preview
Go deeper on NS-050 (NeuShen Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NS-050 (NeuShen Therapeutics).